Strand Therapeutics Inc. announced that it has received over-subscribed round of funding for gross proceeds of $52 million co-led by new investors BeiGene, Ltd., Camford Capital, and Redmile Group, LLC on June 23, 2021. The transaction also included participation from existing investors ANRI and Playground Global, LLC. The company has raised $66 million in funding till date.